Literature-related discovery (LRD): Potential treatments for Multiple Sclerosis

Technological Forecasting and Social Change

Volumn 75, Issue 2, 2008, Pages 239-255

  Kostoff, Ronald N ^a   Briggs, Michael B ^b   Lyons, Terence J ^a  

^a OFFICE OF NAVAL RESEARCH   (United States)

^b Air Force Office of Scientific Research ^*

Author keywords

Discovery; Disparate disciplines; Information retrieval; Innovation; Interdisciplinary; Literature based discovery; Multidisciplinary; Multiple sclerosis; Radical discovery; Science and technology; Text mining; Unconnected disciplines

Indexed keywords

BIOMEDICAL ENGINEERING; DATA MINING; INFORMATION RETRIEVAL; INNOVATION; TEXT PROCESSING;

DISPARATE DISCIPLINES; LITERATURE-BASED DISCOVERY; RADICAL DISCOVERY; TEXT MINING; UNCONNECTED DISCIPLINES;

DISEASE CONTROL;

DATA MINING; DISEASE TREATMENT; INNOVATION; INTERDISCIPLINARY APPROACH; SCIENCE AND TECHNOLOGY;

EID: 38649094887     PISSN: 00401625     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.techfore.2007.11.002     Document Type: Article

References (46)

1. Kostoff R.N., Block J.A., Stump J.A., and Johnson D. Literature-related discovery (LRD): potential treatments for Raynaud's Phenomenon. Technol. Forecast. Soc. Change 75 2 (2008) 203-214 10.1016/j.techfore.2007.11.005
2. Kostoff R.N. Literature-related discovery (LRD): potential treatments for cataracts. Technol. Forecast. Soc. Change 75 2 (2008) 215-225 10.1016/j.techfore.2007.11.006
3. Kostoff R.N. Literature-related discovery (LRD): Potential treatments for Parkinson's Disease. Technol. Forecast. Soc. Change 75 2 (2008) 226-238 10.1016/j.techfore.2007.11.007
4. Kostoff R.N., Briggs M.B., Solka J.L., and Rushenberg R.L. Literature-related discovery (LRD): introduction and background. Technol. Forecast. Soc. Change 75 2 (2008) 165-185 10.1016/j.techfore.2007.11.004
5. Kostoff R.N., Briggs M.B., Solka J.L., and Rushenberg R.L. Literature-related discovery (LRD): Methodology. Technol. Forecast. Soc. Change 75 2 (2008) 186-202 10.1016/j.techfore.2007.11.010
6. Lassmann H., Bruck W., and Lucchinetti C.F. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 17 2 (Apr 2007) 210-218
7. Crayton H.J., and Rossman H.S. Managing the symptoms of multiple sclerosis: a multimodal approach. Clin. Ther. 28 4 (Apr 2006) 445-460
8. Frohman E.M., Filippi M., Stuve O., Waxman S.G., Corboy J., Phillips J.T., Lucchinetti C., Wilken J., Karandikar N., Hemmer B., Monson N., De Keyser J., Hartung H., Steinman L., Oksenberg J.R., Cree B.A., Hauser S., and Racke M.K. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch. Neurol. 62 9 (Sep 2005) 1345-1356
9. Voskuhl R.R. Gender issues and multiple sclerosis. Curr. Neurol. Neurosci. Rep. 2 3 (May 2002) 277-286
10. Hogancamp W.E., Rodriguez M., and Weinshenker B.G. The epidemiology of multiple sclerosis. Mayo Clin. Proc. 72 9 (Sep 1997) 871-878
11. Rodriguez M. Effectors of demyelination and remyelination in the CNS: implications for multiple sclerosis. Brain Pathol. 17 2 (Apr 2007) 219-229
12. Correale J., and Villa A. The blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting. Autoimmunity 40 2 (Mar 2007) 148-160
13. Boccaccio G.L., and Steinman L. Multiple sclerosis: from a myelin point of view. J. Neurosci. Res. 45 6 (Sep 15 1996) 647-654
14. Holmoy T. Immunopathogenesis of multiple sclerosis: concepts and controversies. Acta Neurol. Scand. Suppl. 187 (2007) 39-45
15. Giovannoni G., and Ebers G. Multiple sclerosis: the environment and causation. Curr. Opin. Neurol. 20 3 (Jun 2007) 261-268
16. Stuart W.H. Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management. J. Manag. Care Pharm. 10 3 Suppl B (Jun 2004) S19-S25
17. Kieseier, Wiendl H., Hemmer B., and Hartung H.P. Treatment and treatment trials in multiple sclerosis. Curr. Opin. Neurol. 20 3 (Jun 2007) 286-293
18. Weinstock-Guttman B., and Jacobs L.D. What is new in the treatment of multiple sclerosis?. Drugs 59 3 (Mar 2000) 401-410
19. Kremenchutzky M., Morrow S., and Rush C. The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis. Expert Opin. Drug Saf. 6 3 (May 2007) 279-288
20. Ransohoff R.M. Natalizumab for multiple sclerosis. N. Engl. J. Med. 356 25 (Jun 21 2007) 2622-2629
21. Korniychuk E., Dempster J.M., O'Connor E., Alexander J.S., Kelley R.E., Kenner M., Menon U., Misra V., Hoque R., Gonzalez-Toledo E., Schwendimann R.N., Smith S., and Minagar A. Evolving therapies for multiple sclerosis. Int. Rev. Neurobiol. 79 (2007) 571-588
22. Search Technology, Inc. (2007). http://www.searchtech.com/ http://www.searchtech.com/
23. CLUTO-A Clustering Toolkit (2007). http://www.cs.umn.edu/ http://www.cs.umn.edu/~cluto
24. R.N. Kostoff, J.A. Block, J.L. Solka, M.B. Briggs, R.L. Rushenberg, J.A. Stump, D. Johnson, T.J. Lyons, J.R. Wyatt. Literature-related discovery. DTIC Technical Report Number ADA473438 (http://www.dtic.mil/). Defense Technical Information Center. Fort Belvoir, VA. (In Press).
25. Liu D., Chan S.L., de Souza-Pinto N.C., Slevin J.R., Wersto R.P., Zhan M., Mustafa K., de Cabo R., and Mattson M.P. Mitochondrial UCP4 mediates an adaptive shift in energy metabolism and increases the resistance of neurons to metabolic and oxidative stress. Neuromolecular Med. 8 3 (2006) 389-414
26. Kostoff R.N. Energy restriction. AJCN 74 1 (2001)
27. Eyles D., Almeras L., Benech P., Patatian A., Mackay-Sim A., McGrath J., and Feron F. Developmental vitamin D deficiency alters the expression of genes encoding mitochondrial, cytoskeletal and synaptic proteins in the adult rat brain. J. Steroid. Biochem. Mol. Biol. 103 3-5 (Mar 2007) 538-545
28. Hague T., Andrews P.L., Barker J., and Naughton D.P. Dietary chelators as antioxidant enzyme mimetics: implications for dietary intervention in neurodegenerative diseases. Behav. Pharmacol. 17 5-6 (Sep 2006) 425-430
29. Johnson J.B., Laub D.R., and John S. The effect on health of alternate day calorie restriction: eating less and more than needed on alternate days prolongs life. Med. Hypotheses 67 2 (2006) 209-211
30. Kulkarni A.P., Kellaway L.A., and Kotwal G.J. Herbal complement inhibitors in the treatment of neuroinflammation: future strategy for neuroprotection. Ann. N. Y. Acad. Sci. 1056 (Nov 2005) 413-429
31. Ozugurlu F., Sahin S., Idiz N., Akyol O., Ilhan A., Yigitoglu R., and Isik B. The effect of Nigella sativa oil against experimental allergic encephalomyelitis via nitric oxide and other oxidative stress parameters. Cell. Mol. Biol. 51 3 (Sep 5 2005) 337-342 (Noisy-le-grand)
32. Aktas O., Prozorovski T., Smorodchenko A., Savaskan N.E., Lauster R., Kloetzel P.M., Infante-Duarte C., Brocke S., and Zipp F. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J. Immunol. 173 9 (Nov 1 2004) 5794-5800
33. Muthian G., and Bright J.J. Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte. J. Clin. Immunol. 24 5 (Sep 2004) 542-552
34. Cui H.S., Kim M.R., and Sok D.E. Protection by petaslignolide A, a major neuroprotective compound in the butanol extract of Petasites japonicus leaves, against oxidative damage in the brains of mice challenged with kainic acid. Agric. Food Chem. 53 22 (Nov 2 2005) 8526-8532
35. Martínez Sánchez G., Candelario-Jalil E., Giuliani A., León O.S., Sam S., Delgado R., and Núñez Sellés A.J. Mangifera indica L. extract (QF808) reduces ischaemia-induced neuronal loss and oxidative damage in the gerbil brain. Free Radic. Res. 35 5 (Nov 2001) 465-473
36. Schinella G.R., Tournier H.A., Máñez S., de Buschiazzo P.M., Del Carmen Recio M., and Ríos J.L. Tiliroside and gnaphaliin inhibit human low density lipoprotein oxidation. Fitoterapia 78 1 ((Jan 2007)) 1-6
37. Jainu M., and Devi C.S. Gastroprotective action of Cissus quadrangularis extract against NSAID induced gastric ulcer: role of proinflammatory cytokines and oxidative damage. Chem. Biol. Interact. 161 3 (Jul 10 2006) 262-270
38. Shin T.Y., Park J.S., and Kim S.H. Artemisia iwayomogi inhibits immediate-type allergic reaction and inflammatory cytokine secretion. Immunopharmacol. Immunotoxicol. 28 3 (2006) 421-430
39. Mythilypriya R., Shanthi P., and Sachdanandam P. Restorative and synergistic efficacy of Kalpaamruthaa, a modified Siddha preparation, on an altered antioxidant status in adjuvant induced arthritic rat model. Chem. Biol. Interact. 168 3 (Jul 20 2007) 193-202
40. Ding M., Ye T.X., Zhao G.R., Yuan Y.J., and Guo Z.X. Aqueous extract of Salvia miltiorrhiza attenuates increased endothelial permeability induced by tumor necrosis factor-alpha. Int. Immunopharmacol. 5 11 (2005) 1641-1651
41. Yamashiki M., Mase A., Arai I., Huang X.X., Nobori T., Nishimura A., Sakaguchi S., and Inoue K. Effects of the Japanese herbal medicine 'Inchinko-to' (TJ-135) on concanavalin A-induced hepatitis in mice. Clin. Sci. (Lond) 99 5 (Nov 2000) 421-431
42. Nencini C., Giorgi G., and Micheli L. Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine 14 2-3 ((Feb 2007)) 129-135
43. Xi H., Akishita M., Nagai K., Yu W., Hasegawa H., Eto M., Kozaki K., and Toba K. Potent free radical scavenger, edaravone, suppresses oxidative stress-induced endothelial damage and early atherosclerosis. Atherosclerosis 191 2 (Apr 2007) 281-289
44. Na H.J., Jeong H.J., Shin H.Y., Kim N.S., Um J.Y., Hong S.H., and Kim H.M. Sopoongsan inhibits mast cell-mediated anaphylactic reactions and inflammatory cytokine secretion. Int. Arch. Allergy Immunol. 139 1 (2006) 31-37
45. Zhang R., Kang K.A., Piao M.J., Lee K.H., Jang H.S., Park M.J., Kim B.J., Kim J.S., Kim Y.S., Ryu S.Y., and Hyun J.W. Rhapontigenin from Rheum undulatum protects against oxidative-stress-induced cell damage through antioxidant activity. J. Toxicol. Environ. Health A 70 13 (Jul 2007) 1155-1166
46. Lavhale M.S., and Mishra S.H. Evaluation of free radical scavenging activity of Butea monosperma Lam. Indian J. Exp. Biol. 45 4 (Apr 2007) 376-384